Related Experiment Video
Updated: Dec 6, 2025
11:12
Driving Simulation in the Clinic: Testing Visual Exploratory Behavior in Daily Life Activities in Patients with Visual Field Defects
Published on: September 18, 2012
17.7K
Enhancing the Clinical Utility of DriveSafe DriveAware for People with Huntington's Disease
Monique K Sondhu1, Fiona Fisher2, Julie C Stout1
1School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia.
Journal of Huntington'S Disease
|October 5, 2020
Summary
DriveSafe DriveAware (DSDA) completion time offers valuable cognitive insights for Huntington
Area of Science:
- Neuroscience
- Clinical Psychology
- Gerontology
Background:
- Huntington's disease (HD) significantly impacts cognitive functions crucial for driving.
- The DriveSafe DriveAware (DSDA) cognitive screening tool has shown limitations in accurately assessing driving safety in HD patients.
- Processing speed deficits are an early hallmark of HD, potentially affecting performance on cognitive assessments.
Purpose of the Study:
- To investigate if DSDA completion time provides supplementary cognitive information for individuals with Huntington's disease.
- To determine the correlation between DSDA task completion times and cognitive functions vital for driving in the HD population.
- To explore the potential of incorporating DSDA completion time into clinical decision-making for driving safety assessments in HD.
Main Methods:
- Comparison of DSDA subtest completion times between a group of individuals with Huntington's disease and a control group.
- Correlation analysis between DSDA completion times and specific cognitive functions known to impact driving.
- Utilizing the DriveSafe DriveAware (DSDA) cognitive screening tool for assessment.
Main Results:
- Individuals with Huntington's disease exhibited significantly longer DSDA subtest completion times compared to controls.
- DSDA completion times demonstrated a significant correlation with cognitive functions essential for safe driving.
- The study identified potential discrepancies in DSDA's 'likely to pass' categorizations for some HD participants.
Conclusions:
- DSDA completion time serves as a valuable supplementary cognitive metric for individuals with Huntington's disease.
- Incorporating DSDA completion time may enhance the accuracy of driving safety assessments in HD.
- This approach could lead to more personalized and effective clinical decision-making for HD patients regarding driving.
Related Concept Videos
01:24Parkinson's Disease: Treatment
802
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
802
01:22Alzheimer's Disease: Treatment
630
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
630
01:15Parkinson's Disease: Overview
1.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K
01:26Alzheimer's Disease: Overview
1.4K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.4K
01:29Therapeutic Drug Monitoring: Affecting Factors
105
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
105
01:26Atherosclerosis III: Management
221
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
221